The Clinical Oncology Research Career Development Program (CDP) at the University of California, Davis (UC Davis) will train junior faculty scholars to be independent, patient-oriented cancer researchers. The scholars will conduct translational research to develop laboratory-driven clinical trials designed to optimize novel therapeutic approaches based on the underlying molecular profiles of individual patient tumors or tumor types. The CDP will produce new faculty members from diverse backgrounds who are skilled leaders in team science. UC Davis is well-positioned to train the next generation of clinician scientists in oncology because of its outstanding patient care;long-standing and well-funded infrastructure in clinical-translational investigation (including cancer clinical trials), including our NCI-designated Cancer Center and NCRR-funded Clinical and Translational Science Center (CTSC);experience in laboratory-clinical correlative science;and established inter- and intra-institution consortia, among other resources. Upon successful completion of a three-year, salary-supported core curriculum, Scholars will receive a UC Davis Cancer Center Certificate in Clinical Cancer Research. We will combine key didactic, research, and career development components to produce independent and productive clinical oncology researchers over the course of a three-year program. We will accomplish our goals through the following specific aims: 1) 1) Offer a mentored, competency-based didactic curriculum so Scholars can integrate basic, translational, and clinical science knowledge to discover and/or evaluate more effective treatments for cancer that improve patient outcome;2) Oversee individualized patient oriented research projects (investigator-initiated clinical trials) customized to the interests and needs of each CDP Scholar;and 3) Provide oversight of CDP Scholar training to ensure the progressive development of a high-quality "end-product": a fully competent interdisciplinary-oriented clinician scientist who can successfully conduct translational cancer clinical trials with investigational new agents or devices. The curriculum for the CDP will be guided by two research tracks in Basic/Translational and Clinical science. Each trainee will gain appropriate, integrated didactic and "hands-on" mentored research training following a plan supervised by two senior, independently funded faculty members (one Basic/Translational mentor and one Clinical mentor) to be able to successfully tackle research questions in one of these tracks. We have incorporated unique venues for training in team science and interdisciplinary research into the curriculum in order to take advantage of the strengths of other training programs at UC Davis, particularly those housed in the CTSC. Our overall goal is to develop successful, independent clinical cancer researchers who will be able to work in teams to develop and test new cancer treatments based upon their understanding of the complex mechanisms underlying cancer biology and how they manifest disease in individual patients as well as in broad populations. Thus, we need to make the clinician well-versed in the language of the laboratory scientist and vice-versa. The long-term success of our multidisciplinary approach to understanding and developing targeted treatments for oncologic disease critically depends upon the training of a new generation of multidisciplinary researchers who possess ideas and skills that go far beyond their initial disciplinary boundaries.
The Clinical Oncology Research Career Development Program (CDP) at the University of California, Davis (UC Davis) aims to train junior faculty scholars to be independent, patient-oriented cancer researchers. The scholars will conduct translational research to develop laboratory-driven clinical trials designed to optimize novel therapeutic approaches based on the underlying molecular profiles of individual patient tumors or tumor types. The CDP will produce new faculty members from diverse backgrounds who are skilled leaders in team science by combining key didactic, research, and career development components. The goal is to train independent and productive clinical oncology researchers over the course of a three-year program.
|Naing, Khatija W; Monjazeb, Arta M; Li, Chin-Shang et al. (2015) Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis. J Surg Oncol 111:158-64|
|Semrad, Thomas; Barzi, Afsaneh; Lenz, Heinz-Josef et al. (2015) Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol 20:518-24|
|Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2015) Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol 10:110-5|
|Canter, Robert J; Borys, Dariusz; Olusanya, Abimbola et al. (2014) Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 21:1616-23|
|Shah, Dhruvil R; Bold, Richard J; Yang, Anthony D et al. (2014) Relative value units poorly correlate with measures of surgical effort and complexity. J Surg Res 190:465-70|
|Riess, Jonathan W; Bhattacharya, Nupur; Blenman, Kim R M et al. (2014) Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacol Immunotoxicol 36:182-6|
|Canter, Robert J; Ames, Erik; Mac, Stephanie et al. (2014) Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer 14:756|
|Riess, Jonathan W; Lara Jr, Primo N (2014) Left behind? Drug discovery in extensive-stage small-cell lung cancer. Clin Lung Cancer 15:93-5|
|Abel, Ethan V; Kim, Edward J; Wu, Jingjiang et al. (2014) The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. PLoS One 9:e91983|